氯尼达明治疗不可切除非小细胞肺癌的II期研究。

Phase II study of lonidamine in inoperable non-small-cell lung cancer.

作者信息

Kokron O, Maca S, Scheiner W, De Gregorio M, Ciottoli G B

出版信息

Oncology. 1984;41 Suppl 1:86-9. doi: 10.1159/000225893.

Abstract

31 patients with inoperable non-small-cell lung cancer were treated with Lonidamine at daily doses of 450-900 mg orally. Side effects mostly consisted of myalgias, often severe, and gastrointestinal symptoms. Lonidamine was discontinued in 8 patients because of tumor progression and in 2 on account of side effects. 3 partial responses were observed, 2 in patients with epidermoid tumors.

摘要

31例无法手术的非小细胞肺癌患者接受了氯尼达明治疗，口服剂量为每日450 - 900毫克。副作用主要包括肌痛（通常较为严重）和胃肠道症状。8例患者因肿瘤进展停用氯尼达明，2例因副作用停药。观察到3例部分缓解，其中2例为表皮样肿瘤患者。